Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Budesonide/formoterol combination in COPD: a US perspective

Authors Amir Sharafkhaneh, Amarbir S Mattewal, Vinu M Abraham, et al

Published Date October 2010 Volume 2010:5 Pages 357—366

DOI http://dx.doi.org/10.2147/COPD.S4215

Published 4 October 2010

Amir Sharafkhaneh1,2, Amarbir S Mattewal1, Vinu M Abraham1, Goutham Dronavalli1, Nicola A Hanania1
1Section of Pulmonary, Critical Care Medicine and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; 2Section of Pulmonary, Critical Care Medicine and Sleep Medicine, Medical Care Line, Michael E DeBakey VA Medical Center, Houston, Texas, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease of the lung caused primarily by exposure to cigarette smoke. Clinically, it presents with progressive cough, sputum production, dyspnea, reduced exercise capacity, and diminished quality of life. Physiologically, it is characterized by the presence of partially reversible expiratory airflow limitation and hyperinflation. Pathologically, COPD is a multicomponent disease characterized by bronchial submucosal mucous gland hypertrophy, bronchiolar mucosal hyperplasia, increased luminal inflammatory mucus, airway wall inflammation and scarring, and alveolar wall damage and destruction. Management of COPD involves both pharmacological and nonpharmacological approaches. Bronchodilators and inhaled corticosteroids are recommended medications for management of COPD especially in more severe disease. Combination therapies containing these medications are now available for the chronic management of stable COPD. The US Food and Drug Administration, recently, approved the combination of budesonide/formoterol (160/4.5 µg; Symbicort™, AstraZeneca, Sweden) delivered via a pressurized meter dose inhaler for maintenance management of stable COPD. The combination also is delivered via dry powder inhaler (Symbicort™ and Turbuhaler™, AstraZeneca, Sweden) but is not approved for use in the United States. In this review, we evaluate available data of the efficacy and safety of this combination in patients with COPD.

Keywords: inhaled steroid, bronchodilator, ß2-agonist, lung function, quality of life, COPD exacerbations

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Nanomedicine strategies for treatment of secondary spinal cord injury

White-Schenk D, Shi R, Leary JF

International Journal of Nanomedicine 2015, 10:923-938

Published Date: 29 January 2015

Fluorescent magnetic iron oxide nanoparticles for cardiac precursor cell selection from stromal vascular fraction and optimization for magnetic resonance imaging

Verma VK, Kamaraju SR, Kancherla R, Kona LK, Beevi SS, Debnath T, Usha SP, Vadapalli R, Arbab AS, Chelluri LK

International Journal of Nanomedicine 2015, 10:711-726

Published Date: 20 January 2015

A pilot randomized controlled trial using EEG-based brain–computer interface training for a Chinese-speaking group of healthy elderly

Lee TS, Quek SY, Goh SJA, Phillips R, Guan C, Cheung YB, Feng L, Wang CC, Chin ZY, Zhang H, Lee J, Ng TP, Krishnan KRR

Clinical Interventions in Aging 2015, 10:217-227

Published Date: 9 January 2015

Managing comorbidities in COPD

Hillas G, Perlikos F, Tsiligianni I, Tzanakis N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:95-109

Published Date: 7 January 2015

The relationship between Graves’ ophthalmopathy and dry eye syndrome

Selter JH, Gire AI, Sikder S

Clinical Ophthalmology 2015, 9:57-62

Published Date: 31 December 2014

Evaluation of in vitro glistening formation in hydrophobic acrylic intraocular lenses

Thomes BE, Callaghan TA

Clinical Ophthalmology 2013, 7:1529-1534

Published Date: 25 July 2013

Management of hypoactive sexual desire disorder in women: current and emerging therapies

Rossella E Nappi, Ellis Martini, Erica Terreno, et al

International Journal of Women's Health 2010, 2:167-175

Published Date: 1 July 2010

Duloxetine for the management of fibromyalgia syndrome

Beth A Scholz, Cara L Hammonds, Chad S Boomershine

Journal of Pain Research 2009, 2:99-108

Published Date: 21 July 2009